Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Christian Weyer


  • Evp, Research & Development at Intercept Pharmaceuticals Inc. (ICPT), 2019-07-03
  • See Remarks at Fate Therapeutics Inc (FATE), 2015-04-14
  • Svp, Research & Development at Amylin Pharmaceuticals Inc (AMLN), 2012-08-10
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
ICPT $103.16 333 Officer 19,107 2019-03-01 Filing
ICPT $113.78 1,343 Officer 15,819 2018-11-29 Filing
FATE $9.02 2,262 Officer, Director 0 2014-04-02 Filing
FATE $9.02 7,738 Officer, Director 0 2014-04-01 Filing
AMLN $17.11 1,231 Officer, Other 24,168 2012-03-01 Filing